Financial Performance - The company's operating revenue for the first quarter reached RMB 22,946,212 thousand, representing a year-on-year increase of 6.09%[7] - Net profit attributable to shareholders was RMB 1,958,118 thousand, reflecting a growth of 2.59% compared to the same period last year[7] - Basic and diluted earnings per share were both RMB 1.204, marking a 2.59% increase from the previous year[7] - Total operating revenue for Q1 2024 reached RMB 22.95 billion, an increase of 6.1% compared to RMB 21.63 billion in Q1 2023[29] - Operating profit for Q1 2024 was RMB 2.45 billion, up from RMB 2.35 billion in Q1 2023, reflecting a growth of 4.2%[30] - Net profit attributable to shareholders for Q1 2024 was RMB 1.96 billion, compared to RMB 1.91 billion in Q1 2023, representing an increase of 2.5%[30] - Total comprehensive income for Q1 2024 reached approximately CNY 2.03 billion, a 3.57% increase from CNY 1.96 billion in Q1 2023[32] - Basic and diluted earnings per share for Q1 2024 were CNY 1.204, up from CNY 1.174 in Q1 2023, reflecting a growth of 2.55%[32] Cash Flow - The net cash flow from operating activities was negative at RMB (3,138,187) thousand, a decrease of 10.54% year-on-year[7] - Cash inflow from operating activities in Q1 2024 was approximately CNY 16.79 billion, compared to CNY 15.16 billion in Q1 2023, marking an increase of 10.73%[35] - Net cash flow from operating activities for Q1 2024 was negative CNY 3.14 billion, worsening from negative CNY 2.84 billion in Q1 2023[35] - Cash inflow from investment activities in Q1 2024 totaled CNY 75.78 million, a significant decrease of 73.32% from CNY 284.04 million in Q1 2023[36] - Net cash flow from investment activities was negative CNY 282.99 million in Q1 2024, improving from negative CNY 638.06 million in Q1 2023[36] - Cash inflow from financing activities in Q1 2024 was CNY 6.27 billion, slightly down from CNY 6.77 billion in Q1 2023, a decrease of 7.43%[36] - Net cash flow from financing activities increased to CNY 1.94 billion in Q1 2024, up from CNY 1.57 billion in Q1 2023, representing a growth of 23.36%[36] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 78,703,490 thousand, a slight increase of 0.15% from the end of the previous year[7] - Total liabilities decreased to RMB 39.99 billion as of March 31, 2024, down from RMB 41.91 billion as of December 31, 2023, a reduction of 4.6%[26] - Current liabilities totaled RMB 34.12 billion, a decrease of 5.8% from RMB 36.24 billion at the end of 2023[26] - Non-current liabilities increased to RMB 5.87 billion, up from RMB 5.67 billion, marking a growth of 3.6%[26] - Total equity attributable to shareholders rose to RMB 36.88 billion, an increase of 5.6% from RMB 34.92 billion at the end of 2023[27] Assets Composition - As of March 31, 2024, the total current assets amounted to RMB 55,959,814,735.97, slightly down from RMB 55,983,713,725.09 as of December 31, 2023[23] - The total non-current assets increased to RMB 22,743,675,532.53 from RMB 22,603,164,039.00, indicating a growth in long-term investments[24] - Cash and cash equivalents decreased to RMB 19,754,460,865.10 from RMB 21,308,844,204.44, showing a decline of approximately 7.3%[23] - Accounts receivable rose to RMB 16,715,572,929.90 from RMB 15,112,494,798.69, representing an increase of about 10.6%[23] - The inventory decreased to RMB 9,848,755,918.40 from RMB 11,507,099,742.41, indicating a reduction of approximately 14.4%[23] Other Financial Information - Non-recurring gains and losses for the period totaled RMB 124,577 thousand, after accounting for tax and minority interests[13] - The company received government subsidies amounting to RMB 96,378 thousand during the reporting period[10] - The weighted average return on net assets was 5.45%, a decrease of 0.33 percentage points compared to the previous year[7] - The company did not conduct an audit for the first quarter financial statements[5] - Research and development expenses for Q1 2024 were RMB 186.14 million, slightly higher than RMB 179.39 million in Q1 2023, indicating a focus on innovation[29] - The company reported a tax expense of RMB 420.62 million for Q1 2024, compared to RMB 385.93 million in Q1 2023, reflecting an increase of 9.0%[30] - Other comprehensive income after tax for Q1 2024 was RMB 1.51 million, recovering from a loss of RMB 5.96 million in Q1 2023[30] - The impact of exchange rate changes on cash and cash equivalents was an increase of CNY 2.43 million in Q1 2024, compared to an increase of CNY 1.80 million in Q1 2023[37] Shareholder Information - The total equity attributable to shareholders is not explicitly mentioned but is implied to be stable given the slight changes in total assets and liabilities[24] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[21] - The company has not reported any participation in margin financing or securities lending activities by the top shareholders[21] - There are no significant new strategies or product developments mentioned in the provided documents[22]

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 4,055,678,691.49 for the year 2023, with a base net profit of RMB 1,684,022,544.74[2] - The company achieved a net profit of CNY 1.8 billion, which is a 15% increase compared to the previous year[18] - The company's operating revenue for 2023 reached RMB 75,515,404 thousand, an increase of 6.68% compared to RMB 70,788,155 thousand in 2022[21] - The total profit for the year was RMB 5,110,498 thousand, reflecting a year-on-year increase of 1.33%[29] - The net profit attributable to shareholders for 2023 was RMB 4,055,679 thousand, reflecting a growth of 2.25% from RMB 3,966,522 thousand in the previous year[21] - The company's total assets of the company at the end of 2023 amounted to RMB 78,586,878 thousand, representing a 5.25% increase from RMB 74,665,299 thousand in 2022[21] - The company's total liabilities at the end of 2023 were RMB 41,909,054 thousand, a slight increase of 2.15% from RMB 41,027,441 thousand in 2022[21] - The return on equity attributable to shareholders decreased to 11.61% in 2023 from 12.37% in 2022, a decline of 0.76 percentage points[22] - The company's net assets attributable to shareholders increased to RMB 34,919,281 thousand in 2023, up by 8.90% from RMB 32,065,125 thousand in 2022[21] - The asset-liability ratio improved to 53.33% in 2023, down from 54.95% in 2022, indicating better financial stability[22] Dividend and Profit Distribution - A cash dividend of RMB 0.749 per share (including tax) is proposed, totaling RMB 1,217,717,420.80, based on a total share capital of 1,625,790,949 shares at the end of 2023[2] - The company plans to submit the profit distribution proposal for approval at the 2023 annual general meeting[2] - The company plans to retain the remaining undistributed profits for future distribution, with no capital reserve fund conversion to share capital for this year[2] Risk Management and Compliance - The company has not identified any significant risks that could materially affect its production and operations during the reporting period[4] - The financial report has been audited by Da Xin Certified Public Accountants, providing a standard unqualified audit opinion[1] - The company has confirmed that there are no non-operational fund occupations by controlling shareholders and related parties[3] - The company has not violated any regulatory decision-making procedures in providing guarantees[3] - The board of directors and senior management have ensured the accuracy and completeness of the financial report[1] Market and Product Development - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported a revenue of CNY 10.5 billion for the fiscal year 2023, representing a year-over-year increase of 12%[18] - User data indicates that the company expanded its customer base by 20%, reaching a total of 5 million active users[18] - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations and enhanced delivery systems[18] - Future guidance estimates a revenue growth of 10-15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[18] - The company is investing CNY 500 million in R&D for new technologies aimed at improving drug efficacy and safety[18] - Market expansion efforts include entering two new provinces in China, projected to increase market share by 5%[18] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and distribution capabilities[18] - The company has received regulatory approval for five new drug registrations, expected to contribute an additional CNY 300 million in revenue[18] Research and Development - The company invested a total of RMB 782 million in R&D during 2023, resulting in 11 production approvals for drugs including hydrochloride dapoxetine tablets[35] - The company has established a comprehensive technology innovation system with 5 national-level R&D institutions and 1 national-level enterprise technology center[69] - The company has established 3 provincial and 1 municipal research platforms, along with 6 national and 10 provincial qualifications in research[35] - The company has a strong talent pool, including 3 Nobel Prize winners and over 100 high-level talents with doctoral degrees[70] - The company applied for 134 patents, including 110 invention patents and 24 utility model patents, and received 89 patent grants, with 67 being invention patents[155] Supply Chain and Operations - A new supply chain strategy is being implemented to reduce costs by 8% over the next year[18] - The procurement model has been unified across subsidiaries to enhance cost efficiency and quality control, particularly for bulk Chinese medicinal materials[50] - The company has established multiple medicinal herb planting bases to ensure quality and control costs[147] - The company has a comprehensive supply chain system, integrating raw material procurement, R&D, production, distribution, and retail[66] Marketing and Sales Strategy - The retail network has expanded to 157 outlets, with 51 designated stores for retail business under the "dual-channel" model[32] - The company has established new subsidiaries in Heilongjiang and Shaoguan, enhancing its sales network across Guangdong Province and the Greater Bay Area[32] - The company has a strong marketing network, serving over tens of thousands of customers across more than 30 provinces, cities, and autonomous regions in China[67] - The company is actively expanding its market presence through strategic brand integration and marketing initiatives[64] Regulatory Environment and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue decline of 3.7% year-on-year, totaling RMB 252.06 billion, with total profits down 15.1% to RMB 34.73 billion[42] - The company is focusing on enhancing product and technology quality management, completing the establishment of a drug adverse reaction monitoring system[37] - The pharmaceutical industry is experiencing accelerated restructuring and integration, with mergers and acquisitions becoming the mainstream approach characterized by strategic resource complementarity and strong alliances[184] - The company plans to enhance the consistency evaluation of generic drugs to improve production efficiency and reduce costs, while actively participating in national procurement tenders[119] Future Outlook and Strategic Initiatives - The company plans to enhance its capabilities in quality management and innovation in response to the new manufacturing policies issued in January and December 2023[125] - The company aims to improve its operational management capabilities in its medical services sector, enhancing service levels and establishing complementary relationships between its hospitals[190] - The company will continue to strengthen talent management and risk control mechanisms to support sustainable and high-quality development[193] - The company is committed to strengthening its capital operations, including plans for a new three-board listing and establishing venture capital funds to support innovation projects[192]

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 4,055,678,691.49 for the fiscal year ending December 31, 2023, representing a significant increase from the previous year's net profit of RMB 1,684,022,544.74[6]. - The company's operating revenue for 2023 reached RMB 75,515,404 thousand, an increase of 6.68% compared to RMB 70,788,155 thousand in 2022[26]. - Net profit attributable to shareholders for 2023 was RMB 4,055,679 thousand, reflecting a growth of 2.25% from RMB 3,966,522 thousand in the previous year[26]. - The total profit for the year was RMB 5,110,498 thousand, an increase of 1.33% compared to the previous year[47]. - The net profit after deducting non-recurring gains and losses was RMB 3,635,521 thousand, which is a 9.53% increase from RMB 3,319,308 thousand in 2022[26]. - The company's total assets at the end of 2023 amounted to RMB 78,586,878 thousand, up 5.25% from RMB 74,665,299 thousand in 2022[26]. - The company's total liabilities increased by 2.15% to RMB 41,909,054 thousand compared to RMB 41,027,441 thousand in the previous year[26]. - The gross profit margin for the main business improved slightly to 18.61%, an increase of 0.05 percentage points year-on-year[62]. - The total comprehensive income for the year ended December 31, 2023, was approximately CNY 4.25 billion, a slight decrease of 0.3% compared to CNY 4.26 billion in 2022[145]. Dividends and Profit Allocation - The proposed cash dividend is RMB 0.749 per share, totaling RMB 1,217,717,420.80, based on a total share capital of 1,625,790,949 shares[6]. - The company plans to retain the remaining undistributed profits for future allocation, with no capital reserve fund conversion to share capital for this year[6]. Compliance and Transparency - The board of directors has confirmed the accuracy and completeness of the financial report, which was audited by Da Xin Certified Public Accountants[6]. - The company is committed to maintaining transparency and has ensured that all information is available on the Shanghai Stock Exchange and Hong Kong Stock Exchange websites[5]. - The company emphasizes compliance with Chinese accounting standards in its financial reporting[5]. - The annual report is available in both Chinese and English, with the Chinese version being the authoritative text in case of discrepancies[8]. - The audit committee confirmed that the financial reports accurately reflect the company's financial status without any significant misstatements or fraud[126]. Market and Industry Trends - The pharmaceutical industry is experiencing a transformation period, facing challenges such as price reductions and rising raw material costs, while also benefiting from policies promoting innovation and development[25]. - The overall trend in the pharmaceutical industry indicates continuous growth in demand due to an aging population and increased health awareness, supported by government policies[24]. - The company is focused on future growth strategies, including potential market expansions and new product developments[5]. Product and Service Development - The company operates 28 pharmaceutical manufacturing entities, including 12 time-honored Chinese medicine brands, with 324 products included in the National Medical Insurance Catalog[18]. - The health products segment includes beverages and health supplements, with strong brand value in the herbal tea market, particularly the Wanglaoji brand, which holds a significant market share in China[20]. - The company is expanding its healthcare services and medical device investments, focusing on traditional Chinese medicine and modern elderly care[22]. - The company is leveraging digital and intelligent technologies to create new development opportunities in the pharmaceutical sector[24]. - Key products such as Qingkailing series and Wanglaoji herbal tea saw significant sales growth during the reporting period[49]. Financial Management and Investments - The company's cash flow from operating activities decreased by 41.37% to RMB 4,103,625 thousand from RMB 6,999,076 thousand in 2022[26]. - The company invested RMB 3.34 billion to establish the WBA Alliance Fund, marking a significant step in its transformation in the biopharmaceutical health industry[57]. - Research and development expenses totaled RMB 782,144 thousand, a decrease of 4.55% compared to RMB 819,454 thousand last year[59]. - The company plans to enhance its marketing integration and innovation models, particularly in the OTC market and e-commerce, to drive growth[104]. Employee and Organizational Development - The total number of employees in the group is 28,048, with 2,062 in the parent company and 25,986 in major subsidiaries[111]. - The company emphasizes employee development through a comprehensive training system that covers all levels of staff, from production workers to senior management[118]. - The company has a diverse educational background among employees, with 10,057 holding bachelor's degrees and 799 holding postgraduate degrees[115]. Audit and Internal Control - The audit committee held 11 meetings in 2023, reviewing the financial reports for 2022 and the first three quarters of 2023, ensuring compliance and accuracy[123]. - The company has established a robust internal control system, ensuring compliance with laws and regulations, and protecting shareholder rights[128]. - The company reappointed Da Xin Certified Public Accountants as its financial audit firm for 2023, confirming their qualifications and independence[124]. Strategic Initiatives - The company will focus on the integration of digital economy and pharmaceutical health industry in 2024, aiming for high-quality development across various business segments[104]. - The company plans to accelerate its overseas market expansion to increase international brand recognition[107]. - The company will continue to strengthen capital operations and explore opportunities for mergers and acquisitions to optimize its business structure[109].

Financial Performance - Operating revenue for Q3 2023 reached RMB 18,214,219 thousand, an increase of 3.58% year-on-year[2] - Net profit attributable to shareholders was RMB 980,002 thousand, reflecting a growth of 10.81% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 840,145 thousand, with a slight increase of 0.78% year-on-year[2] - The basic earnings per share for Q3 2023 was RMB 0.603, up by 10.81% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached RMB 58.18 billion, an increase of 6.3% compared to RMB 54.81 billion in the same period of 2022[14] - Operating profit for the first three quarters of 2023 was RMB 4.76 billion, up from RMB 4.46 billion in the same period of 2022, reflecting a growth of 6.6%[15] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.47 billion in 2022, representing an increase of 9.3%[15] - Basic and diluted earnings per share for the first three quarters of 2023 were both RMB 2.332, up from RMB 2.137 in the same period of 2022[16] - The total comprehensive income attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.48 billion in 2022, an increase of 8.5%[16] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 74,353,331 thousand, a decrease of 0.42% from the end of the previous year[2] - Total assets increased to RMB 74.35 billion in 2023 from RMB 74.67 billion in 2022, indicating a slight decrease of 0.4%[13] - Total liabilities decreased to RMB 37,977,384,691.70 from RMB 41,027,440,697.52, a reduction of 7.5%[11] - The company’s total liabilities and equity amounted to RMB 36.38 billion in 2023, up from RMB 33.64 billion in 2022, reflecting an increase of 8.2%[13] Shareholder Information - Shareholders' equity attributable to the parent company increased to RMB 34,660,070 thousand, representing an increase of 8.09% year-on-year[2] - The company had a total of 91,342 common shareholders at the end of the reporting period[4] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares[5] - The company reported a total of 732,305,103 shares held by Guangzhou Pharmaceutical Group Co., Ltd., the largest shareholder[6] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was RMB 901,626 thousand, showing a significant decrease of 72.67% year-on-year[4] - Operating cash inflow for the first three quarters of 2023 was RMB 53.47 billion, a slight increase from RMB 52.59 billion in the same period of 2022, representing a growth of 1.68%[17] - Cash outflow from operating activities totaled RMB 52.57 billion in 2023, compared to RMB 49.29 billion in 2022, indicating an increase of 6.56%[18] - Net cash flow from operating activities decreased to RMB 901.63 million in 2023, down 72.66% from RMB 3.30 billion in 2022[18] - Cash inflow from investment activities was RMB 2.36 billion in 2023, significantly higher than RMB 253.22 million in 2022[18] - Net cash flow from investment activities was negative at RMB 2.21 billion in 2023, an improvement from a loss of RMB 5.87 billion in 2022[18] - Cash inflow from financing activities was RMB 10.80 billion in 2023, slightly lower than RMB 11.38 billion in 2022, a decrease of 5.06%[19] - Net cash flow from financing activities turned negative at RMB 916.78 million in 2023, compared to a positive flow of RMB 1.29 billion in 2022[19] - The ending cash and cash equivalents balance as of September 2023 was RMB 18.59 billion, down from RMB 19.73 billion at the end of September 2022, a decrease of 5.78%[19] Current Assets and Receivables - As of September 30, 2023, total current assets amounted to RMB 52,924,980,357.93, a decrease of 7.5% from RMB 57,064,311,513.29 on December 31, 2022[8] - Cash and cash equivalents decreased to RMB 19,873,967,228.77 from RMB 22,499,552,770.75, representing a decline of 11.5%[8] - Accounts receivable increased to RMB 16,521,846,517.80, up 11.2% from RMB 14,857,591,768.49[8] - Total non-current assets reached RMB 21,428,350,404.03, an increase of 21.5% compared to RMB 17,600,987,263.45 at the end of 2022[9] - The total amount of accounts payable rose to RMB 12,620,557,642.25, an increase of 12.7% from RMB 11,200,347,828.21[10] Research and Development - Research and development expenses for the first three quarters of 2023 were RMB 579.48 million, down from RMB 664.39 million in 2022, a decrease of 12.8%[14] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[7] Foreign Currency Impact - The company recorded a net foreign currency translation difference of RMB 5.07 million in the first three quarters of 2023, compared to RMB 17.80 million in 2022, indicating a decrease of 71.5%[16] - The impact of exchange rate changes on cash and cash equivalents was positive at RMB 6.75 million in 2023, compared to a negative impact of RMB 876.30 thousand in 2022[19]

Financial Performance - The company reported no interim dividend distribution for the six months ending June 30, 2023[1]. - The financial report for the reporting period was prepared in accordance with Chinese accounting standards and is unaudited[2]. - The board of directors confirmed the accuracy and completeness of the financial report[1]. - The company's operating revenue for the reporting period reached RMB 39,970,331 thousand, representing a year-on-year increase of 7.39% compared to RMB 37,220,451 thousand in the same period last year[13]. - Net profit attributable to shareholders was RMB 2,811,248 thousand, an increase of 8.54% from RMB 2,589,996 thousand in the previous year[13]. - The net profit after deducting non-recurring gains and losses was RMB 2,598,509 thousand, reflecting a growth of 12.96% compared to RMB 2,300,375 thousand last year[13]. - The total profit for the same period was RMB 3,532,692 thousand, reflecting a year-on-year growth of 6.02%[37]. - Basic earnings per share rose to RMB 1.729, an increase of 8.54% from RMB 1.593 in the same period last year[13]. - The weighted average return on net assets was 8.40%, a slight decrease of 0.13 percentage points compared to 8.53% in the previous year[13]. - The company's net cash flow from operating activities decreased significantly to RMB (740,710) thousand, a decline of 143.26% from RMB 1,712,214 thousand in the previous year[13]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[10]. - The financial report includes a section on potential risks that the company may face[10]. - The company has not faced any situation where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the semi-annual report[2]. - The company has established an online risk control supervision platform to improve risk warning standards and enhance risk identification accuracy[103]. - The company aims to strengthen internal control and risk management systems to ensure the achievement of strategic goals[100]. Corporate Governance - The company has fully complied with the corporate governance code as per the Hong Kong Stock Exchange regulations[100]. - In the first half of 2023, the company organized 1 shareholders' meeting, 6 board meetings, and 5 supervisory meetings[100]. - The company completed the re-election of the board and supervisory committee members in May 2023, appointing new executives and committee members[101]. - The company conducted a self-assessment of its internal control and social responsibility, resulting in the publication of the 2022 Internal Control Evaluation Report and the 2022 ESG Report[100]. Environmental Compliance - The company reported that its chemical pharmaceutical plant exceeded emission standards for several pollutants, including COD at 114.17 mg/L, which is above the standard of 500 mg/L[106]. - The company is committed to enhancing its environmental performance and reducing pollutant discharge through ongoing assessments and compliance measures[110]. - The company has multiple facilities with nitrogen oxides (NOx) emissions exceeding the regulatory limits, indicating a need for improved emission controls[108]. - The company has established a total of 12 pollution control facilities across various production lines, enhancing its environmental compliance efforts[114]. - The company has committed to continuous improvement in its environmental performance, aligning with national standards and regulations[112]. Market Position and Strategy - The company is a leader in the antibiotic market with a complete industrial chain from raw materials to formulations, aiming to establish a top brand in oral antibiotics[21]. - The company has 323 products included in the National Medical Insurance Catalog and 331 products in the provincial medical insurance catalog, indicating strong market presence[19]. - The company is expanding its medical services and healthcare investments, with projects like Baiyunshan Hospital and healthcare service companies[24]. - The company is focusing on innovation and high-end formulation production technology as part of the "14th Five-Year Plan"[25]. - The company is actively expanding its market presence and enhancing its product offerings through continuous research and development efforts[35]. Related Party Transactions - The total amount of related party transactions during the reporting period was 185,190,000 RMB, with various types of transactions including sales of goods and provision of services[154]. - The company reported a related party transaction amount of 76,352,000 RMB for sales of goods at market price[156]. - The company engaged in related party transactions with Baiyunshan Hehuang Company amounting to 85,305,000 RMB for sales of goods at market price[156]. - The company provided advertising agency services to Guangzhou Baiyunshan Cultural Industry Co., Ltd. for 134,000 RMB[156]. Investment and Capital Expenditure - The group plans to spend approximately RMB 2.677 billion on capital expenditures in 2023, with RMB 867 million already spent in the first half of the year[60]. - The company invested RMB 401 million in R&D during the first half of 2023, obtaining six production approvals for new drugs and one clinical trial approval[42]. - The company has confirmed that the accounting policy changes will not have a significant impact on its financial position, operating results, and cash flows for the current period[172]. - The company has utilized RMB 243.90 million of the raised funds in the first half of 2023, with a cumulative investment of RMB 7,130.35 million as of June 30, 2023[178]. Employee and Labor Relations - The total number of employees in the group as of the end of the reporting period is 23,493, with total employee wages amounting to approximately RMB 2.05 billion in the first half of 2023[194]. - The company has implemented a comprehensive training management system to promote employee development, covering all levels from frontline workers to senior management[196]. - The company emphasizes equal employment and respects diverse backgrounds, firmly opposing any form of discrimination[195]. Shareholder Information - As of June 30, 2023, the number of shareholders holding the company's stock was 91,239, with 91,188 holding A-shares and 51 holding H-shares[185]. - The top ten shareholders held a total of 732,305,103 shares, representing 45.04% of the total share capital[185]. - The largest shareholder, Guangyao Group, maintained its shareholding at 732,305,103 shares, with no changes during the reporting period[186].

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年半年度報告摘要 一、 重要提示 1.1 本公司半年度報告摘要摘自本公司截至2023年6月30日止六個月的2023年半年度報告全 文，投資者欲瞭解詳細內容，應當仔細閱讀將刊載於上交所網站（http://www.sse.com.cn） 等中國證監會指定網站和港交所網站（http://www.hkex.com.hk）上的半年度報告全文。 1.2 本公司董事會、監事會及其董事、監事、高級管理人員保證本摘要內容的真實、準確、完 整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司董事出席了第九屆董事會第三次會議，其中，獨立非執行董事陳亞進先生因公務未 能親自出席本次董事會會議，委託獨立非執行董事黃民先生代為出席並行使表決權；執行 董事劉菊妍女士、獨立非執行董事黃龍德先生和孫寶清女士以通訊方式參加了 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年第一季度報告 重要內容提示 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）、監事會及董事、監事、高級管理人 員保證季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別 和連帶的法律責任。 本公司董事長李楚源先生、財務副總監劉菲女士及財務部副部長吳楚玲女士保證季度報告中財務信 息的真實、準確、完整。 第一季度財務報表是否經審計 □是 ✔否 季度報告分別以中、英文兩種語言編訂，兩種文本若出現解釋上的歧義時，以中文本為準。 ...

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 3,966,522,218.54 for the year 2022, with a base net profit of RMB 1,756,732,233.08, resulting in a 10% statutory surplus reserve of RMB 175,673,223.31[1] - The company reported a total distributable profit of RMB 8,063,724,029.08 after accounting for the cash dividend and retained earnings[1] - The company achieved a net profit of CNY 1.8 billion, which is a 15% increase compared to the previous year[12] - The company’s operating revenue for 2022 reached RMB 70,788,155 thousand, representing a year-on-year increase of 2.57% from RMB 69,014,052 thousand in 2021[13] - The total profit for the year was RMB 5,043,244 thousand, an increase of 6.78% compared to the previous year[21] - The net profit attributable to shareholders for 2022 was RMB 3,966,522 thousand, an increase of 6.63% compared to RMB 3,719,878 thousand in 2021[13] - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management and pricing strategies[12] - The company reported a significant increase in investment income, which rose by 117.56% to RMB 421,175 thousand[59] Dividends and Profit Distribution - A cash dividend of RMB 7.32 per 10 shares (including tax) is proposed, totaling RMB 1,190,078,974.67, based on a total share capital of 1,625,790,949 shares as of the end of 2022[2] - The remaining undistributed profits will be carried forward to the next distribution, with no capital reserve transfer to increase share capital planned for this year[2] - As of December 31, 2022, the company's distributable reserves amounted to RMB 8,063,724 thousand[181] Market Expansion and Product Development - User data indicates that the company expanded its customer base by 20% in the last year, reaching over 5 million active users[12] - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations and enhanced delivery systems[12] - Future outlook includes a projected revenue growth of 10-15% for the upcoming fiscal year, driven by market expansion and new product launches[12] - The company aims to expand its market reach into Southeast Asia, targeting a 5% market share within the next two years[12] - The company is exploring strategic acquisitions to enhance its market presence and product portfolio, with a budget of CNY 500 million allocated for potential mergers and acquisitions[12] Research and Development - Research and development expenditure increased by 25% to CNY 300 million, emphasizing the commitment to innovation and new technology[12] - The company has established 5 national-level R&D institutions and 1 national-level enterprise technology center[58] - The company has a total of 193 ongoing research projects, focusing on new drug development, generic drug consistency evaluation, and health food development[141] - The company applied for 88 patents, including 73 invention patents and 15 utility model patents, and received a total of 94 patent authorizations[144] - The company is focusing on innovative drugs and biopharmaceuticals, as well as the consistency evaluation of generic drugs[141] Operational Efficiency and Cost Management - The company is implementing a new supply chain strategy to enhance efficiency and reduce operational costs by 10% over the next year[12] - The company has established a unified procurement platform to enhance bargaining power and reduce procurement costs, integrating procurement for raw materials, packaging, and equipment[42] - The procurement model for major products is through tender procurement, with overall costs increasing due to rising prices of herbs like Rehmannia and Pueraria, while costs for Schisandra have decreased[134] - The company has implemented strict quality control measures in production, adhering to national GMP standards throughout the manufacturing process[44] Risk Management and Compliance - There are no significant risks that could materially affect the company's operations during the reporting period[3] - The company has established a comprehensive risk management system to identify, assess, and manage significant risks, ensuring effective internal controls[194] - The audit committee confirmed that the internal control and risk management systems are adequate and effective, complying with corporate governance codes[195] - The company conducts semi-annual evaluations of its internal control and risk management systems to ensure continuous improvement[195] Industry Trends and Challenges - The pharmaceutical manufacturing industry in China saw a revenue of RMB 2,911.14 billion in 2022, a year-on-year decrease of 1.6%, and a total profit of RMB 428.87 billion, down 31.8%[32] - The pharmaceutical industry is expected to benefit from supportive policies for innovation and development, particularly in high-end formulation production technology[30] - The company is facing challenges from the regulatory environment, particularly regarding the standardization of traditional Chinese medicine and the pressure to control costs[171] - The company is actively participating in the accelerated restructuring and integration of the pharmaceutical industry, characterized by strategic resource complementarity and mergers[171] Corporate Governance and Social Responsibility - The company is committed to social responsibility, ensuring drug supply during the pandemic and supporting rural revitalization efforts[28] - The company has adhered to the corporate governance code, with minor deviations noted due to the chairman's absence at a shareholders' meeting[191] - The company has established a public account for forfeited contributions under the enterprise annuity plan, benefiting employees still in the plan[189]

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2022年年度報告摘要 一、 重要提示 1.1 本公司本年度報告摘要摘自本公司截至2022年12月31日止的2022年年度報告全文，為全面 瞭解本公司的經營成果、財務狀況及未來發展規劃，投資者應當仔細閱讀將刊載於上交所 網站（http://www.sse.com.cn)和港交所網站（http://www.hkex.com.hk)等網站上的年度報告 全文。 1.2 本公司董事會、監事會及董事、監事、高級管理人員保證本摘要內容真實性、準確性、完 整性，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司全體董事出席了第八屆第二十七次董事會會議，其中，副董事長楊軍先生因公務未 能親自出席本次董事會會議，委託副董事長程寧女士代為出席並行使表決權。 ...

Financial Performance - Operating revenue for Q3 2022 reached RMB 17,585,465 thousand, representing a year-on-year increase of 1.00%[2] - Net profit attributable to shareholders for Q3 2022 was RMB 884,371 thousand, an increase of 9.27% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 833,660 thousand, up by 5.23% year-on-year[2] - Total revenue for the first three quarters of 2022 reached RMB 54.81 billion, a 2.36% increase from RMB 53.54 billion in the same period of 2021[15] - Net profit attributable to the parent company's shareholders for the first three quarters of 2022 was RMB 3.68 billion, compared to RMB 3.51 billion in 2021, reflecting a growth of 4.83%[17] - The company achieved a net profit margin of approximately 6.70% for the first three quarters of 2022, compared to 6.54% in the same period of 2021, reflecting improved profitability[16] Assets and Liabilities - Total assets as of the end of the reporting period amounted to RMB 69,552,608 thousand, reflecting a growth of 5.19% from the previous year[2] - Total liabilities reached RMB 35,673,611,929.67 as of September 30, 2022, up from RMB 34,791,121,204.96 at the end of 2021[13] - Non-current assets totaled RMB 16,694,174,290.70 as of September 30, 2022, compared to RMB 13,307,215,302.50 at the end of 2021, indicating a significant increase[12] - The total equity attributable to shareholders of the parent company increased to RMB 31.43 billion as of September 30, 2022, from RMB 29.06 billion at the end of 2021, marking an increase of 8.19%[14] Cash Flow - Cash flow from operating activities showed a significant decline of 42.97% year-on-year, primarily due to changes in cash collection timing and reduced sales revenue[5] - Operating cash flow for the first three quarters of 2022 was RMB 3,299,469,998.07, a decrease of 42.9% compared to RMB 5,785,483,481.52 in the same period of 2021[20] - Cash inflow from operating activities totaled RMB 52,588,121,756.76, down from RMB 53,172,636,613.14 year-on-year, reflecting a decline of 1.1%[20] - Cash outflow from operating activities increased to RMB 49,288,651,758.69, compared to RMB 47,387,153,131.62 in the previous year, marking an increase of 4.0%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 98,511[6] - The basic earnings per share for Q3 2022 was RMB 0.544, up by 9.27% year-on-year[2] - Earnings per share for the first three quarters of 2022 were RMB 2.137, an increase from RMB 2.037 in the same period of 2021[18] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to RMB 664.39 million, up from RMB 604.71 million in 2021, indicating a focus on innovation[15] Government Subsidies - The company received government subsidies amounting to RMB 39,187 thousand during the reporting period, closely related to its normal business operations[3] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[40]